Jing Liang 🇺🇦
36.6K posts
Jing Liang 🇺🇦
@AppleHelix
Entrepreneur. Drug hunter. Anti-ideologues, Anti-medical nihilists, Optimist My NGO: https://t.co/yDWRnOYAyY https://t.co/SOf8c5OZm6
Katılım Aralık 2009
5K Takip Edilen11.1K Takipçiler
Jing Liang 🇺🇦 retweetledi
What is the real-world risk of recurrence from HR+/HER2- EBC? In our latest #JNCI article, including data from >7000 pts (Flatiron) we report 7y recurrence rates of 14% for N1 and N0 high-risk pts and up to ~40% in N2-3, supporting use of adjuvant CDK4/6i. academic.oup.com/jnci/advance-a…
English
Jing Liang 🇺🇦 retweetledi
Pretty cool
Yago Garitaonaindía@YGaritaonaindia
📣 New in #EJC: among PD-(L)1 responders, durability tracks response depth, not tumor type Our nationwide cohort 🇩🇰: 2,127 responders (#melanoma, #RCC, #NSCLC) • Within CR & within PR, PFS near-identical across tumors • PR vs CR = dominant factor Two papers, two faces of the same coin 🪙: response depth, not tumor type, drives the risk of acquired resistance to IO Trial-level (@JNCCN) + real-world (#EJC), same conclusion Cheers to @DoniaMarco & @CCITdk Full paper 👇👇 #LCSM #IO
English
Jing Liang 🇺🇦 retweetledi
Another win for Dizal, but how do US patients get hold of Zegfrovy? Via @ApexOnco -> oncologypipeline.com/apexonco/node/…
English
Jing Liang 🇺🇦 retweetledi
Dizal started out as a spinout from Astra's Shanghai-based Asian R&D centre. AFAIK $AZN still holds a 24% equity stake in Dizal.
English
Jing Liang 🇺🇦 retweetledi
Next indication opportunity for $QTTB?
Kitching Laboratory@KitchingLab
Time is critical in AAV: dampening kidney inflammation prevents damage Why not target effector T cells - leave other T cells alone? Our paper in @NDTSocial defines IL-7Ra as a target doi.org/10.1093/ndt/gf… Anti-IL-7Ra Abs are in Phase 2 trials - alopecia @Q32Bio ?an AAV therapy
English
Can anyone suggest a more updated review of 3 types of immunity than this? Ideally easy to understand like this one.
jacionline.org/article/S0091-…
English
@GerardCaelles Hermano Torres only got its 3rd star recently. I also thought Lasarte until recently was also 2 stars
English
Surprised to learn that New York (~8 million people) has only 5 three-Michelin-star restaurants.
Barcelona (~2 million people), by contrast, has 4: Disfrutar, ABaC, Lasarte, and Cocina Hermanos Torres.
Sheel Mohnot@pitdesi
TIL the Bay Area has 44% (7/16) of the Michelin 3 starred restaurants in the US New York has 5, LA has 2
English
100%!
Fixing Stuyvesant admission stats is not the same as actually fixing subpar math and science education.
Corey Walker 🇺🇸@CoreyWriting
Stuyvesant is probably the worst school to try racial balancing in because it is a huge pressure cooker with little student support. It is not uncommon for students to go there are flounder. It also just does not matter where a student attends high school, and most students are better off at a less competitive high school with strong academic support.
English
Jing Liang 🇺🇦 retweetledi
What's left unsaid is that high achieving black & Latino kids go to elite NYC private schools & not Stuyvesant. Prep for Prep gives 681 black & Latino students free private school tuition. Asian kids are not eligible for these scholarships so they go to Stuy & Bronx Science.
Gothamist@Gothamist
Just 3 Black students admitted to NYC's elite Stuyvesant High School, data shows gothamist.com/news/just-3-bl…
English
Jing Liang 🇺🇦 retweetledi
CVS Aetna CEO discusses why insurers don’t cover GLP-1s - which he describes as unproven ROI.
He conveniently leaves out the fact that the only ROI that matters for an insurer is $ saved so long as a member is a member. And in our employed healthcare system, that’s 3 years or so on average.
So even if these miracle drugs
saved downstream costs and sickness in 10 or 20 years, it would be irrelevant to large commercial insurers. The savings would accrue to insurer down the line - very likely Medicare.
Plus I’m sure his Caremark PBM loves the GLP-1 rebate candy which he also does not discuss.
I’m glad he sat for the interview but he told about half the story and then went on a tangent about EMRs.
English
Jing Liang 🇺🇦 retweetledi
“Our education system is failing certain kids, so let’s get rid of one of the key ways we can measure this and do something about it”
or….we could just fund a much more robust early childhood education system for the kids that need it most and not break public education for the kids that had the system work
Lincoln Restler@LincolnRestler
1 in 5 NYC public school students are Black, but at Stuy - our most prestigious high school - 3 of ~800 incoming Freshmen are Black. We urgently need state legislation to modify the admissions process. A single test should never be only factor deciding who gets in & who doesn’t.
English
Jing Liang 🇺🇦 retweetledi
🧬🎯Precision oncology has a geography 🌏🌍🌎problem!
Tumor-agnostic therapy is moving cancer care beyond the organ of origin. Yet testing, reimbursement, trials, and workforce gaps still block access...
Congratulations to @JiaJennyLiu and colleagues on this important review. A timely roadmap for turning tumor-agnostic innovation into equitable global access.
@ASCO @JCO_ASCO @herbloong @BenWestphalen @curijoey @VivekSubbiah @OncoAlert @OpenMedicineHQ @jrgralow @ASCOPres
English
Jing Liang 🇺🇦 retweetledi
follicular atresia occurs at an accelerating rate
~1.5 m in utero
~300k at puberty
~100k at 20 yrs
~10k late 30s
~1k around 51 yrs
maybe enroll at 45, run 6 mo-1 yr
Jing Liang 🇺🇦@AppleHelix
@CharlesMBrenner Very interesting! What is the natural rate of decline? Wonder how long this trial will need to be run
English
@CharlesMBrenner Very interesting! What is the natural rate of decline? Wonder how long this trial will need to be run
English
Jing Liang 🇺🇦 retweetledi
you could run a placebo-controlled trial in which you look for protection of antral follicle count by either transvaginal ultrasound or 3D ultrasound as the primary endpoint
protection of antral follicles should prolong fertility & hormone balance
Jing Liang 🇺🇦@AppleHelix
This is an interesting area for drug discovery. But what would the regulatory path be for delaying menopause? Seems like a very difficult trial to run and recruit.
English
Jing Liang 🇺🇦 retweetledi
"Developing a successful biopharma therapy costs a multinational company about 2.7 times more compared to a Chinese company on a levelized cost basis"
Biopharma R&D: The evolving formula for discovery and development mckinsey.com/mgi/our-resear… via @McKinsey_MGI
English
Jing Liang 🇺🇦 retweetledi
For the benefit of those who haven’t seen the review of the ball hitting the camera cable before England’s equaliser on Fox Sports…
English